<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00845988</url>
  </required_header>
  <id_info>
    <org_study_id>06-2008-104</org_study_id>
    <nct_id>NCT00845988</nct_id>
  </id_info>
  <brief_title>Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders</brief_title>
  <official_title>Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders Having Drug-induced Weight Gain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to investigate metabolic changes and maintaining efficacy
      in stabilized patients with bipolar disorders who have pharmacologically induced weight gain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  reduced treatment adherence due to metabolic side effects

        -  suggested advantages of aripiprazole in metabolic profile over other antipsychotics or
           mood stabilizers

        -  randomized trial of switch from previous drugs to aripiprazole
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight BMI Glucose and lipid profiles CGI-BP KOQOL SWN-K</measure>
    <time_frame>0, 4, 8, 12, 18, 26 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ECG prolactin SAS BAS UKU-SERS-Pat-Korean version</measure>
    <time_frame>0, 4, 8, 12, 18, 26 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Bipolar Disorders</condition>
  <condition>Metabolic Complication</condition>
  <arm_group>
    <arm_group_label>treatment as usual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients showing weight gain while receiving treatment with risperidone, olanzapine, quetiapine, or clozapine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>switch to aripiprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>aripiprazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aripiprazole</intervention_name>
    <description>dosage form : po recommended dosage : more than 10mg/day duration : 28 weeks</description>
    <arm_group_label>treatment as usual</arm_group_label>
    <arm_group_label>switch to aripiprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with bipolar disorders (I, II, NOS) diagnosed with DSM-IV criteria

          -  age between 18 and 65

          -  Decisional capacity is adequate to provide informed consent or has an authorized
             appropriate surrogate decision maker. in a syndromal remission state at least for 2
             months : CGI - BP â‰¤ 3

          -  patients who have exhibited a clinically significant increase in body weight after
             starting the administration of their current antipsychotic (ie &gt;7% weight gain)

        Exclusion Criteria:

          -  diagnosis of eating disorder, substance abuse, and psychotic disorder

          -  history of neurological and medical illness

          -  pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyooseob Ha, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2009</study_first_submitted>
  <study_first_submitted_qc>February 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <last_update_submitted>December 4, 2013</last_update_submitted>
  <last_update_submitted_qc>December 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Kyooseob Ha</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Bipolar disorder</keyword>
  <keyword>metabolic complication</keyword>
  <keyword>Aripiprazole</keyword>
  <keyword>Weight gain</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Antipsychotic</keyword>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Psychopharmacology</keyword>
  <keyword>Open Label</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

